Cross-linking is a medical procedure that combines the use of ultra-violet light and riboflavin eye drops.
Collagen crosslinking involves removal of the surface corneal epithelial cell layer, saturation of the cornea with 0.1 % riboflavin for 30 minutes (1 drop is applied every 2 minutes) followed by application of UV light for 30 minutes. The corneal thickness needs to be over 400 microns for the procedure to be safe and effective. Collagen Cross-linking has been used for many years in the field of Dentistry. Corneal Collagen Cross-Linking with Riboflavin was first used in 1998 to treat Keratoconus.
The technique was developed by Theo Seiler in Dresden. Treatments started in 1998, although initially only a handful were carried out each year, and it was not until a few years later that the Dresden clinic was treating over 100 patients per year with CXL. CXL works by increasing collagen ‘crosslinks’ which are the natural “anchors” within the cornea.
These anchors are responsible for preventing the cornea from bulging out and becoming steep and irregular i.e like it is with keratoconus.
This process has been shown in laboratory and clinical studies to increase the amount of collagen cross-linking in the cornea and therefore strengthen the cornea
OK- let’s start with two things.
Firstly, Collagen cross linking is not a cure for keratoconus. This is not my opinion, it is a fact- anyone proclaiming it as a cure is being somewhat misleading. The NKCF agrees . Many people have now had CXL and it is indeed a promising treatment for keratoconus, that is worth investigating to see if it is suitable for you.
What is CXL? Who should have it?
So what is it exactly? CXL speeds up the ageing and hardening process of your cornea, thus reaching the point where your keratoconus would have stopped progressing naturally. So if you are 20, your cornea might then be about 25 years older than you- so to speak. It is for this reason that Moorfields set 40 years old as the upper age limit for their CXL trials (after 40 most corneas thicken naturally) A side effect is that it can be hardened and flattened at the same time. CXL is equivalent to lifetime progressive thickening of the cornea, so in theory this is a treatment that should only need to be done once. Furthermore the older you are the less likely it is that CXL will be of any use to you.
Esteemed Consultant Ophthalmic Surgeons such as Samer Hamada believe that keratoconus is a childhood disease and as such the earlier you are diagnosed and treated with CXl to prevent the disease progressing, the better, this of course can also mean that you might avoid a corneal graft in later life.
If you have been wearing RGP lens for 20 years and your KC is stable and is not progressing you are unlikely to be a viable candidate- although you would make the data look good. KC does stop progressing naturally, but it is up to you if you want to speed that up.
Only 1 in 4 need a graft, the 3 in 4 have lens and glasses and manage brilliantly for life. That said if your KC remains unstable, again, CXL is worth investigating. The aim of this treatment is to stop the progression of keratoconus in mild or early stages, and prevent further deterioration in vision and with any luck- the need for corneal transplantation. Glasses or contact lenses will most likely still be needed following the cross-linking treatment (as your prescription may well have changed somewhat) but it is hoped that long term it might stop further deterioration of vision.
The use of this procedure has gradually increased, with 400+ centres around the world now performing this procedure in over 100 countries. The procedure has been refined over the years, with adjustments to the Riboflavin soak time and to the UVA light exposure time and energy levels. Corneal Collagen Cross Linking with Riboflavin is also known as CXL, CCR, CCL, C3-R and KXL.
The Ophthalmic community is starting to see the benefits of prophylactic (preventative) treatment using Cross-linking and this procedure is now starting to be offered as a standalone procedure or in conjunction with corneal laser refractive surgery (PRK and IntraLASIK). There are currently 3 available systems that provide the UVA light source. The UV-X™ Illumination System is the most widely used system currently.
Soosan Jacob, MS, FRCS, DNB, presented early results of contact lens-assisted cross-linking (CACXL) at the Indian Intraocular Implant and Refractive Surgery meeting in Chennai, India in 2013. “My technique of CACXL acts by artificially increasing the thickness of the ultraviolet (UV) absorption medium anterior to the endothelium by means of pre-corneal riboflavin film, a riboflavin-soaked contact lens and a pre-contact lens riboflavin film,” Jacob said in an interview with Ocular Surgery News.
With this technique, cross-linking can be performed on a larger number of patients and on patients with thinner corneas than those who undergo conventional corneal cross-linking, Jacob said.
CACXL is not dependent on swelling properties of the cornea, as in hypo-osmolar cross-linking, and produces a more stable riboflavin film, she said.
The two basic types of corneal crosslinking are:
Epithelium off, which means the thin layer covering the eye’s surface is scraped off, allowing for faster penetration with liquid riboflavin.
How is it done?
Transepithelial corneal crosslinking (epithelium on) is where the corneal epithelial surface is left intact, which requires a longer riboflavin loading time. There are various schools of thought as to which version of CXL is ‘best’ depending on where you are in the world. There is controversy as to whether the top layer of cornea (the epithelium) should be removed before the Riboflavin is applied. The epithelium layer is designed to prevent water, chemicals and so on penetrating into the eye. It therefore acts somewhat like “waterproofing” but does allow some molecules to pass through, which is why drops such as antibiotic and steroid eye drops can be used.
“Epi off” is favoured by most UK & European clinics as it is felt that penetration of the Riboflavin is most effective with this method. Epi-off crosslinking by definition is invasive. Your corneal epithelium is scraped off, like having a gigantic scratch on your eye which is painful and causes blurry vision during the healing phase.
Complications of epi-off crosslinking can be quite serious too: corneal infections/ulcers, corneal infiltrates, corneal scarring, corneal haze, and delayed epithelium healing. These epi-off complications came out from the U.S. Crosslinking Clinical Trial and from IROC in Switzerland at the 2009 American Academy of Ophthalmology Annual Meeting – Refractive Surgery Subspecialty Day. Cornea nerve damage from epi-off crosslinking takes 6 months to recover as reported by the University of Crete at the same meeting. (source http://www.keratoconusinserts.com/crosslinking.htm)
After CXL, the eye will be sore for 3 or 4 days, a bandage lens is worn and painkillers given. Patients cannot wear a contact lens for several months after the treatment. Another side effect is the significant vision changes for up to 6 months as your eye goes through healing with epi-off crosslinking due to the epithelium remodelling process that occurs after the epithelium grows back on the cornea surface.
CXL does carry the risk of potentially serious side effects (infective keratitis, a risk of scarring on the surface of the cornea and a risk of haze).
“Epi on” is favoured by some clinicians who feel they can increase penetration through the epithelium by combining the Riboflavin with other eye drops, such as Boxer Wachler- who renamed it Holcomb C3-R and says it is non-invasive – and that they have NEVER seen any of the above complications with it.
However recent evidence tends to show that cross linking is more long lasting with epi off. This is why most clinical trials world wide use the epi off procedure. The epithelium heals very quickly after removal – overnight in fact. However, while it is healing, there is a certain amount of pain and sensitivity to light.
Therefore epi on is a much more comfortable option, but may not be as effective long term. Any pain with either system can be controlled with drugs, of course. While crosslinking is used in virtually every country around the world, it is still in the FDA approval process in the United States.
So after almost 20 years of study results and clinical records from the likes of the NHS in the UK, the evidence does suggest that CXL is proving to be of real benefit in improving the quality of life for some people with KC. As with any treatment you need tests and to see an expert in the field to ascertain whether it is right for you- before you part with as much as £2,000 in a private clinic or seek an NHS referral.
USA- CXL and the FDA
Finally, in April 2016, the U.S. Food and Drug Administration (FDA) gave approval to Avedro Inc.’s corneal cross-linking system to treat patients with progressive keratoconus and post-LASIK ectasia.
Studies on corneal cross-linking go back more than a decade, and countries in Europe have offered their approved treatment for years. In the U.S., some doctors of optometry have been co-managing patients with cross-linking for years, informing them that it was “off label” and had not yet been approved in this country. But that approval has come, and it was worth the wait for the good it will do patients.
The Avedro system is the first corneal cross-linking treatment ever approved in the USA.
“Quite frankly, the U.S. was lagging behind the rest of the world, so I’m very happy about its approval,” Dr. Morgenstern says.
He adds, “It is really a significant increase in scope of treatment for patients with keratoconus. It has been proven through study on top of study on top of study.”
CXL IN THE UK- ON THE NHS
CXL IS available on the NHS in the UK DESPITE what you may have been told by your GP or hospital practitioner. However it is not as yet WIDELY available, and it is all down to a. Funding and b, whether your Optom or surgeon has adopted it, as not all have. So if you want it or at least more info you need to do your homework, and see where it is and ask for a referral- you may not get one of course. Privately various clinics offer it such as Optegra, Face & Eye Manchester and so on. Many UK members of Facebook.com/groups/keratoconusgb have had CXL on the NHS, so do join and enquire there.
NICE has released their guidance on collagen cross linking. The guidance advocates epithelium off CXL due to good evidence on safety and efficacy, in the UK. CXL is suitable for adults and children and is offered if indicated. The growing evidence means that patients in the UK should have access to treatment in the NHS without having to go privately. The Corneoplastic Unit at Queen Victoria Hospital in East Grinstead has been doing this under NHS for many years. Patients choice means that you can ask your GP to refer you to anywhere in the country for quality treatment- so if you want CXL or to learn more about it- speak to your GP or your optom for more information.
Should I have CXL?
If you have early or mild diagnosed KC that is seen to be progressing – you may consider cxl. Some patients opt to have cxl not waiting for obvious signs of progression (vision changes/loss) and having two topographical tests 6 months apart to detect this progression.
History of change of glasses/CL prescription or refraction over last year can be enough evidence to suggest that cxl would be worth doing. Seek advice from your Optom or eye clinic.
CXL – collagen cross linking
ACXL or Keraflex or KXL is Accelerated corneal collagen crosslinking, such as Avedro’s KXL system which reduces the UVA exposure time to less than 3 minutes. The Avedro KXL Accelerated Cross-Linking system is newer and has not yet been approved in the US by the FDA (see below). The Avedro KXL Accelerated Corneal Collagen Cross-Linking system has been approved in Europe and by Health Canada and other countries.
The most used term for epi off corneal collagen crosslinking is CXL, usually referred to as the Dresden protocol, which includes removal of the corneal epithelium and UVA irradiation for 30 minutes.
C-3R Holcomb or C3R, is the epi-on corneal collagen crosslinking method trademarked by Brian Boxer Wachler, MD, in 2003 in the USA.
CACXL is Contact lens-assisted cross-linking, a newer technique for cross-linking in corneas less than 400 microns thick.